SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001047469-20-000944
Filing Date
2020-02-19
Accepted
2020-02-19 17:28:23
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B5 a2240748z424b5.htm 424B5 554710
2 G261620.JPG g261620.jpg GRAPHIC 20049
3 G797372.JPG g797372.jpg GRAPHIC 22046
4 G178942.JPG g178942.jpg GRAPHIC 25876
  Complete submission text file 0001047469-20-000944.txt   650012
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 424B5 | Act: 33 | File No.: 333-215387 | Film No.: 20631336
SIC: 2834 Pharmaceutical Preparations